Digest Network How does it work
Network
/
Society
Na
Not verified

Natera, Inc.

What we write about

BiotechnologyHealthIndustriaMedicine - variousOncology

81 Press releases

View all press releases
05/12/2025
Biotechnology
Health
Pharmaceuticals
Oncology
stock market
Natera Acquires Foresight Diagnostics
Source
Natera, Inc.
Issuer
Business Wire
1.00
0
03/12/2025
Scienza
Biotechnology
Pharmaceuticals
Oncology
Health
Sanità
Eventi
Industria
New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting
Source
Natera, Inc.
Issuer
Business Wire
1.00
0
02/12/2025
Eventi
Industria
Scienza
Biotechnology
Pharmaceuticals
Oncology
Health
Sanità
Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium
Source
Natera, Inc.
Issuer
Business Wire
1.00
0
19/11/2025
Industria
Eventi
Oncology
Associations / Professional
Health
Biotechnology
Pharmaceuticals
Employees Volunteer Over 1,500 Hours During Natera’s Annual Volunteer Month
Source
Natera, Inc.
Issuer
Business Wire
1.00
0
12/11/2025
Labour market
Industria
Biotechnology
Health
Oncology
Natera Integrates with Flatiron Health’s OncoEMR® Platform
Source
Natera, Inc.
Issuer
Business Wire
1.00
0
06/11/2025
Oncology
Health
Biotechnology
Scienza
WEB AND SOCIAL NETWORK
Phones and Miscellaneous
stock market
Natera Reports Third Quarter 2025 Financial Results
Source
Natera, Inc.
Issuer
Business Wire
1.00
0
31/10/2025
Industria
Biology
Biotechnology
Oncology
Health
Windows / Shopping
Medicine - various
Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT
Source
Natera, Inc.
Issuer
Business Wire
1.00
0
30/10/2025
WEB AND SOCIAL NETWORK
Phones and Miscellaneous
Finance
stock market
Oncology
Communication
Sanità
Health
Biotechnology
Windows / Shopping
Natera to Report its Third Quarter Results on November 6, 2025
Source
Natera, Inc.
Issuer
Business Wire
1.00
0
28/10/2025
Industria
Oncology
Health
Biotechnology
Sanità
Medicine - various
Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity
Source
Natera, Inc.
Issuer
Business Wire
1.00
0
20/10/2025
Eventi
Industria
Biotechnology
Health
Medicine - various
Oncology
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
Source
Natera, Inc.
Issuer
Business Wire
1.00
0

Contact details

Social Media

Followers
0
Compatibility
0